Navigation Links
Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
Date:12/7/2007

DALLAS, Dec. 7 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) announced today that it has demonstrated the ability, using the company's proprietary Cobalamin(TM) technology, to significantly reduce glucose levels in an animal model of diabetes, through its oral insulin product candidate. Several formulations using Cobalamin, which is based upon the body's natural absorption of vitamin B12 in the gastrointestinal tract, were tested in an animal model of diabetes. Additional pre-clinical studies are planned.

Access has patents and formulations based on vitamin B12 attachment to polymers and nanoparticles which carry an attached or encapsulated drug. The vitamin B12 absorption mechanism transfers the macrostructure from the gut to blood, facilitating the absorption of drugs that otherwise could not be delivered orally. Access' Cobalamin(TM) technology has the potential to enable and improve oral bioavailability of active drugs which currently have to be administered by injection, including proteins, antibodies and siRNA.

"While Access already has proof-of-principle data using this technology with a variety of proteins and peptides, we are delighted to have attained preclinical study results which indicate that a meaningful pharmacological effect can be achieved," stated Dr. David P. Nowotnik, Access' Senior Vice President, Research and Development. "As a result of this very promising result, we plan to complete a short series of formulation optimization studies and then to select a clinical development candidate."

Access intends to develop the Cobalamin(TM) oral delivery technology in collaboration with other pharmaceutical and biotechnology companies. Access has in the past and continues to conduct sponsored research programs with leading pharmaceutical companies based on its Cobalamin technology. The company is also actively seeking additional partners for both its oral insulin and other potential program
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014   Unique Pizza ... Inc.: OTC Pink: UPZS), a Delaware Corporation, is ... agreement with Larasan Pharmaceutical Corporation ("Larasan"), a nature-based pharmaceutical ... to the agreement, US-based Larasan will work with ... frozen pizza through Larasan,s vast distribution network throughout ...
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... (EURONEXT: SAN and NYSE: SNY ) today ... alirocumab in people with hypercholesterolemia met their primary efficacy ... low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to ... antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... Coordinators, Inc. (PCI) is pleased to announce it has ... Limited (Penn Pharma). Penn Pharma is headquartered in Tredegar, ... Kingdom and operates regional offices in ... Tokyo , Japan. Penn Pharma offers both drug development ... manufacturing, as well as Clinical Packaging, Labeling, and global ...
Breaking Medicine Technology:Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5
(Date:7/30/2014)... July 30, 2014 Shabaikai is an ... forests of the Pomo Indians located on the shores ... the river Shabaikai, meaning ‘crooked snake’. Clarkson takes the ... and the violence of prohibition and organized crime, providing ... River. Here, the most powerful men in the world ...
(Date:7/30/2014)... Antonio, TX (PRWEB) July 30, 2014 ... with Christus Spohn Health, recently announced the proposed naming ... TX: the Dr. Hector P. Garcia Family Health Center. ... state-of-the-art primary health care services, including comprehensive chronic disease ... It will also be a pioneering medical home model ...
(Date:7/30/2014)... July 30, 2014 Naomi Fried, ... the Board of Directors of the American Telemedicine ... the Association, which has a mission to promote ... through telecommunications and information technology. , “Both Naomi ... Association, possess extraordinary expertise and are well known ...
(Date:7/30/2014)... have identified a protein that could help doctors decide ... that makes radiotherapy more effective, according to a study* ... (BJC). , The team from The University of Manchester, ... whose bladder tumour had high levels of a protein, ... carbogen oxygen mixed with carbon dioxide gas ...
(Date:7/30/2014)... Rhode Island Hospital researchers have found that a ... reduce depression and other symptoms in informal caregivers, ... dementia. The study is published online in advance ... Dementia . , "Those caring for people with ... often under a great deal of pressure," said ...
Breaking Medicine News(10 mins):Health News:Bill E. Clarkson Releases Debut Fact-Based Novel, Shabaikai 2Health News:Dr. Hector P Garcia Memorial Foundation Supports New Health Care Facility 2Health News:American Telemedicine Association Welcomes Two New Members to the Board of Directors 2Health News:Scientists pinpoint bladder cancer patients who could benefit from 'tumor-softening' treatment 2Health News:Study: Telephone support program beneficial for caregivers of those with dementia 2
... A paper by Indiana University-Purdue University Indianapolis ... to improve identification of breast cancer tissue by ... scientific paper in the "bioinformatics and biomedical applications ... The best scientific paper award ...
... "fused" with a groupa bond even stronger than group identificationwill ... outsiders, conclude researchers in a new study published in ... Science. This intense bond to a group may help explain ... B. Swann, Jr., of the University of Texas, came up ...
... and adolescents have become fatter over the last ... Bloomberg School of Public Health and National Institute ... across socio-demographic groups over time and found U.S. ... such as body mass index (BMI), waist circumference ...
... and women in the Troms Study in northern Norway has reported ... cognitive tests. The subjects (average age 58 and free of ... with a range of cognitive function tests. Among women, there was ... consumed wine at least 4 or more times over two ...
... By Steven Reinberg HealthDay Reporter , TUESDAY, Aug. ... of imaging to guide the needle now make up the majority ... the use of these minimally invasive biopsies increased from 59 percent ... trend which is likely to continue, one expert noted. A biopsy ...
... (CLASS) Act a largely overlooked component of the 2010 ... to transform long-term care financing in the United States from ... issue of Public Policy & Aging Report ... SCAN Foundation , this installment of PPAR features ...
Cached Medicine News:Health News:People with 'fused' identities are willing to die for their social group 2Health News:Overweight American children and adolescents becoming fatter 2Health News:Moderate drinking, especially wine, associated with better cognitive function 2Health News:Less Invasive Biopsies Gain Favor 2Health News:CLASS Act analysis reveals America's long-term care future 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: